Altered Expression of the m6A Methyltransferase METTL3 in Alzheimer’s Disease is a research paper published in eNeuro (2020). On theSindex it has a DataRank of 0.769. It has been cited 168 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.769
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Australian Research Council
Grant: DE170100112
Discovery Early Career Researcher Award - Grant ID: DE170100112
Department of Health | National Health and Medical Research Council
Grant: GNT112919
Department of Health | National Health and Medical Research Council
Grant: GNT1128436
Impact of interleukin-18 on Alzheimer’s disease
Department of Health | National Health and Medical Research Council
Grant: GNT1139469
Targeting inflammation as a biomarker and treatment for Alzheimer's disease
University of Queensland
Grant: ECR1834545
NIA NIH HHS
Grant: P50 AG016573
National Health and Medical Research Council (NHMRC)
Grant: 1128436
Impact of interleukin-18 on Alzheimer’s disease
Australian Research Council (ARC)
Grant: LE100100074
Facilities for automated high-throughput slide scanning and stereology
National Health and Medical Research Council (NHMRC)
Grant: 1139469
Targeting inflammation as a biomarker and treatment for Alzheimer's disease
National Institutes of Health
Grant: 5P50AG016573-09
CORE--NEUROPATHOLOGY CORE
Clem Jones Centre for Ageing Dementia Research
FWCI
8.80
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Additional file 1 of N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease
Additional file 1 of N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease
Additional file 1 of FTO-targeted siRNA delivery by MSC-derived exosomes synergistically alleviates dopaminergic neuronal death in Parkinson's disease via m6A-dependent regulation of ATM mRNA
Additional file 1 of FTO-targeted siRNA delivery by MSC-derived exosomes synergistically alleviates dopaminergic neuronal death in Parkinson's disease via m6A-dependent regulation of ATM mRNA
Additional file 1 of N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis
Additional file 2 of N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis
Additional file 3 of N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis
Additional file 1 of N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis
Additional file 2 of N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis
Additional file 3 of N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis
Additional file 4 of N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis
Additional file 4 of N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis